Chapter 74 The boss is really, I cried to death

Chinese name: Ponatinib

English name: Ponatinib

Chemical formula: C29H27F3N6O

Molecular weight:532.56

Acidity coefficient:12.99±0.70

Drug use: Effective in multi-target inhibition of Abl, PDGFRα, VEGFR2, FGFR1 and Src.

After Xu Nuo gained an in-depth understanding of the new generation tyrosine kinase inhibitor drug "ponatinib" synthesized by Professor Huang Wenqiang's team, he also gained a new understanding of the drug treatment of chronic myelogenous leukemia.

Actually.

Ponatinib is a third-generation tyrosine kinase inhibitor that has been developed and approved for marketing in the previous life on Earth.

It's just that the technology of Blue Star in this parallel world is relatively lagging behind, and in the field of drugs for the treatment of chronic myelogenous leukemia, it is still stuck on imatinib.

Therefore, ponatinib is a more powerful new drug for chronic myelogenous leukemia.

"Professor Huang, how much advantage does our ponatinib have over imatinib from the European Nori Pharmaceutical Group?"

Xu Nuo asked Professor Huang Wenqiang seriously.

After all, this is not Xu Nuo’s field of expertise, so I still have to ask Professor Huang Wenqiang for advice.

"Compared with imatinib, our new drug can obtain cytogenetic and molecular responses more quickly, especially deep molecular responses. It should be able to achieve better results for intermediate and high-risk patients in the chronic phase.

, and it is also more likely to reduce disease progression. As for the specifics, we need to wait until our new drug undergoes clinical trials before we can get more detailed data."

Huang Wenqiang introduced.

The word "should" used by Professor Huang Wenqiang here when talking about drug efficacy is because this is only comparative information obtained during the research and development process. In fact, it must be confirmed through clinical trials before we can say with certainty the drug's efficacy ratio.

Imatinib is strong.

"What about the side effects?"

Xu Nuo asked again.

As a chemically synthesized drug, if it has a good effect on diseases, it will definitely have side effects, which may be major or minor problems.

After all, there is a saying.

It's medicine that is three parts poison.

The same is true for ponatinib. Its efficacy may be stronger than imatinib from the European Nori Pharmaceutical Group, but it is not an invincible miracle drug after all.

As Professor Huang Wenqiang just said, it can inhibit multi-target receptors and greatly reduce the progression of chronic myelogenous leukemia.

In other words, when patients take this new drug, chronic myelogenous leukemia will basically no longer become serious, and it can effectively stabilize the disease.

So as long as you insist on taking it, patients in the early and middle stages will basically be no different from normal people, and patients with medium and high risks can stabilize their condition and prevent it from getting worse.

"Mr. Xu, during the research process, we did find that ponatinib has certain side effects for patients, such as possible adverse reactions on cardiovascular and thrombosis. Xiao Yang, what do you think of our views on ponatinib?

Bring over the research data on side effects and report it to your boss."

Huang Wenqiang called out to a young man in the team.

"Professor, boss."

Young man Yang Jin came to Xu Nuo with a tablet in his hand: "During the synthesis research of ponatinib, we also conducted some corresponding research on the side effects of chemical drugs in the treatment of chronic myelogenous leukemia.

Possible side effects include congestive heart failure, hypertension, arrhythmia and bone marrow suppression."

"So are these side effects significant?"

Xu Nuo knew that things like high blood pressure and arrhythmia would be fine if they were mild, but if the impact was greater, it might not be good.

"The side effects we are studying, such as congestive heart failure, hypertension, arrhythmia, etc., should be at the monitoring level. The side effects will not be too serious and health monitoring needs to be maintained. However, bone marrow suppression may lead to thrombocytopenia and neutropenia.

, and anemia, etc., the dose may need to be interrupted or reduced at that time.”

Yang Jin continued to explain.

At this time, Huang Wenqiang said seriously: "These possible side effects will ultimately require more detailed data in clinical trials. I prefer that the side effects will be lower in clinical trials."

Xu Nuo probably understood.

Although it seems that there are many side effects, such as affecting blood pressure, arrhythmia, bone marrow suppression, etc.

However, these side effects are completely acceptable for the therapeutic effect of ponatinib.

To put it simply, this medicine can save your life and prevent your disease from getting worse, but you need to maintain periodic safety monitoring of your blood pressure, heart rate, platelets, etc.

"So when can I apply for the first phase of clinical trials?"

After understanding the pharmacological mechanism, drug efficacy, drug side effects and other information, Xynotox would like to know when the clinical trial can be applied to start.

Huang Wenqiang replied: "For clinical trials, we will collect and organize the data before clinical research in the past few days. After the National Day, we can apply to the National Pharmaceutical Administration for the first phase of clinical trials."

Under normal circumstances, the birth of a new drug follows a strict process.

First, you need to choose a disease, and then conduct drug exploration based on this disease.

Xynomic’s biomedical laboratory naturally chose chronic myelogenous leukemia.

This is also the direction that Professor Huang Wenqiang and these young graduate students and doctoral students have been working on before, but due to limited funds, the progress has been slow.

After arriving at Xynotabine's biomedical laboratory, and with the addition of Xynotabine's exchange for [a new generation of tyrosine kinase inhibitors], it was basically equivalent to skipping drug exploration and drug research.

Two stages.

After a new drug is synthesized, the next step is clinical trials.

However, before clinical trials, preclinical safety, evaluation, toxicity, etc. need to be studied. It is obvious from Xu Nuo’s inquiry just now that Professor Huang Wenqiang and others are already doing this.

"Okay, if you need anything in the laboratory, just let me know. I look forward to hearing good news from you."

"Don't worry, Mr. Xu, we will definitely develop this new drug as soon as possible." Yang Jin said with confidence.

It was at the boss Xu Nuo, Yang Jin and other top medical students that they found the true value of life.

Because this new tyrosine kinase inhibitor drug can save countless patients with chronic myelogenous leukemia at home and abroad. These patients have been taking expensive drugs for many years and have almost no hope in life.

Once this new drug comes out, its efficacy and pricing will be much more cost-effective than imatinib.

According to Yang Jin's estimation, if this drug is approved for marketing after clinical trials are completed, it can at least bring the price of tyrosine kinase inhibitors to less than 10,000 yuan.

This is definitely good news for patients with chronic myelogenous leukemia.

Just imagine, a box of medicine previously cost as much as 24,000 yuan, and you would need to take one box a month.

And when ponatinib is launched, a box of medicine only costs a few thousand yuan, and a box of medicine can be taken for more than a month, so the cost of taking medicine has suddenly dropped.

And even if the medicine costs several thousand yuan, it doesn’t matter. Our domestically produced medicines have a good chance of being included in the medical insurance. By then, patients will be able to take ponatinib for about a thousand yuan.

Already.

In fact, the medical insurance negotiation team has been working hard over the years to negotiate with the European Nori Pharmaceuticals Group to join the medical insurance.

It’s just that the European Nori Pharmaceuticals Group has been dragging its feet. They are unwilling to give up such a large pharmaceutical market in China, because data shows that the number of patients with chronic myelogenous leukemia in China is increasing every year.

How could the Europeans give up on such a huge, rising market so easily?

This is also the main reason why the price of imatinib from European Nori Pharmaceuticals Group has remained high and has not been included in medical insurance.

Anyway, patients in China can make a lot of money just by suffering. What reason do European capitalists have to show mercy?

"Mr. Xu, walk slowly."

"Everyone has worked hard, and I will give you a bonus at the end of the year."

Xu Nuo encouraged Yang Jin and the others.

"Thank you boss!"

All the young people in the laboratory were very excited when their boss Xu Nuo said there would be bonuses at the end of the year.

They work in real biomedical laboratories, and the salaries they receive are already very high, plus bonuses, which directly makes each of them feel that they have chosen to study medicine for a lifetime, study hard to study for a PhD, and engage in scientific and technological research.

Totally worth it.

After leaving the biomedical laboratory.

Xu Nuo was ready to go around the company again, so he said to his assistant Wen Ruohan: "Xiao Wen, please take me to each department of the company to have a look."

However.

After Xu Nuo finished speaking, there was no response for a long time.

What's going on?

"Xiao Wen?"

Xu Nuo stopped walking forward and called his assistant Wen Ruohan behind him.

Still no response.

Xu Nuo had no choice but to turn around, only to find that Wen Ruohan was not behind him, but seemed to be in a daze not far away.
To be continued...